Oxadiazoles and thiadiazoles as TGF-beta inhibitors

A C1-C4, dialkylamino technology, applied in the field of oxadiazoles and thiadiazoles as TGF-β inhibitors, can solve the problems of expensive peptides, unclear local skin levels, and reduced skin wound healing

Pending Publication Date: 2020-09-11
SOUTHERN RES INST & IP +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Systemic administration of LSKL-blocking peptides did not reduce Smad signaling or reduce skin wound healing in diabetic mice, however these studies did not address the effect of direct application of LSKL to wounds, and it is unclear Are local skin levels of LSKL sufficient to alter local TGF-β activation (Lu et al. (2011) Am J Pathol 178:2573-2586)
[0014] Although peptides containing the amino acid sequence LSKL capable of stimulating TGF-β activity are known, these peptides are generally expensive and difficult to synthesize

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oxadiazoles and thiadiazoles as TGF-beta inhibitors
  • Oxadiazoles and thiadiazoles as TGF-beta inhibitors
  • Oxadiazoles and thiadiazoles as TGF-beta inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0054] The present invention can be understood more readily by reference to the following detailed description of the invention and the Examples included therein.

[0055] Before the compounds, compositions, articles of manufacture, systems, devices and / or methods of the present invention are disclosed and described, it is to be understood that they are not limited to particular synthetic methods unless otherwise indicated, or that they are not limited to particular reagents unless otherwise indicated, and therefore Of course it can vary. It is also to be understood that terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods and materials are now described.

[0056] Although aspects of the present invention may be described and claimed in a particular ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-beta and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended tobe limiting of the present invention.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 577,608, filed October 26, 2017, the contents of which are hereby incorporated by reference in their entirety. [0003] Statement Regarding Federally Funded Research [0004] This invention was made with government support under Grant No. 1R01 CA175012 awarded by the National Institutes of Health. The government has certain rights in this invention. Background technique [0005] TGF-β is a central regulator of chronic liver disease by inducing fibrogenesis responses (Weskirchen and Tacke (2016) Dig Dis 34:410-422; Katz et al. (2016) Cancer letters 379:166-172; Yoshida et al. (2014) ) Int J Oncol 45: 1363-1371; Fabregat et al. (2016) The FEBS journal 283: 2219-2232; Xu et al. (2016) J Histochem Cytochem 64: 157-167). Although infiltrating macrophages are a source of TGF-β, hepatic stellate cells are an important source of TGF-β in liver fibrosis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4245C07D271/06C07D285/08
CPCA61K31/433A61K31/4245A61P37/06A61K31/4709A61P35/00A61K31/4439Y02P20/55
Inventor M·J·苏托V·V·古普塔B·马修J·墨菲-乌尔里希
Owner SOUTHERN RES INST & IP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap